SCHEDULE 13G/A: JPMorgan Chase & Co. Discloses 2.8% Stake in Tenaya Therapeutics

JPMorgan Chase & Co. has filed an amended Schedule 13G, reporting a beneficial ownership of 2.8% in Tenaya Therapeutics, Inc.'s common stock as of February 28, 2025.

Summary

• JPMorgan Chase & Co. filed an Amendment No. 1 to Schedule 13G regarding its beneficial ownership in Tenaya Therapeutics, Inc.
• The filing indicates that JPMorgan Chase & Co. beneficially owns an aggregate of 2,283,914 shares of Tenaya Therapeutics, Inc. Common Stock.
• This ownership represents 2.8% of the class of securities.
• JPMorgan Chase & Co. holds sole voting power over 1,901,559 shares and sole dispositive power over 2,283,914 shares.
• The filing was made by JPMorgan Chase & Co. as a parent holding company, with relevant subsidiaries identified as JPMorgan Chase Bank, National Association and J.P. Morgan Investment Management Inc.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: This is a factual disclosure of beneficial ownership and does not contain information that would indicate a positive or negative sentiment regarding the issuer's performance or prospects.

Future Outlook

NA

Management Comments

• "To the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

This filing is a routine disclosure of institutional ownership, common in the financial industry, reflecting a passive investment stake by a major financial institution in a biotechnology company. It does not provide specific insights into Tenaya Therapeutics' operational performance or the broader biotech industry trends.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake, which can influence market perception and liquidity.
• Investment Professionals: Offers data points for tracking institutional ownership and potential investor sentiment.

Key Dates

Keywords

JPMorgan Chase & Co., Tenaya Therapeutics Inc., Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Institutional Ownership, Investment Management